WO1998056389A1 - Prevention of ovarian cancer by administration of a vitamin d compound - Google Patents
Prevention of ovarian cancer by administration of a vitamin d compound Download PDFInfo
- Publication number
- WO1998056389A1 WO1998056389A1 PCT/US1998/011737 US9811737W WO9856389A1 WO 1998056389 A1 WO1998056389 A1 WO 1998056389A1 US 9811737 W US9811737 W US 9811737W WO 9856389 A1 WO9856389 A1 WO 9856389A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vitamin
- cells
- compound
- dosage
- neoplastic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- Vitamin D and its analogues and derivatives are taught to have possible utility in the treatment, rather than prevention, of cancers by retarding tumor growth and in stimulating the differentiation of malignant cells to normal cells.
- 1,25-dihydroxyvitamin D 3 possesses potent antileukemic activity by virtue of inducing the differentiation of leukemia cells to non-malignant macrophages.
- Vitamin D and its metabolic products while potentially useful in retarding tumor growth have the disadvantage that they are very potent calcemic agents that cause elevated blood calcium levels by stimulating intestinal calcium absorption and bone calcium resorption. Accordingly, there has been a desire in the art for Vitamin D analogues and derivatives having variant activities such that, for example, antileukemic activity is enhanced without concomitant enhancement of calcemic activity. Frampton et al., Cancer Research 43: 4443-4447 (1983) disclose the inhibition of human breast cancer cell growth in vitro.
- Narvaez et al. Endocrinology Vol. 137, No. 2 pp 400-409 (1996) are in accord with the references discussed above.
- Narvaez et al. teach (1) that Vitamin D can have effects on malignant cells, but the effects are cell type specific and unpredictable and (2) that, to the extent tested, Vitamin D did not have any effect on non-malignant cells.
- o Narvaez et al. teach that 1,25-dihydroxyvitamin D 3 is a negative growth regulator of breast cancer epithelial cells and that its effects are mediated via the nuclear vitamin D receptor (VDR).
- VDR nuclear vitamin D receptor
- the invention provides methods of inhibiting conversion of non-neoplastic ovarian epithelial cells to neoplastic cells comprising administering to a female subject an amount of Vitamin D or a biologically active analogue or derivative thereof effective to increase apoptosis in non- neoplastic ovarian epithelial cells of a female subject.
- the invention further provides methods of increasing apoptosis of non-neoplastic ovarian epithelial cells of a female subject comprising administering to a female subject an amount of Vitamin D or a biologically active analogue or derivative thereof effective to increase apoptosis in ovarian epithelial cells of the subject.
- Apoptosis is a process whereby a genetic program within the 5 cell is activated to trigger a specific series of events within the cell eventually leading to the death and efficient disposal of the cell.
- Richard Lockshin, Zahra Zakeri The Biology of Cell Death and Its Relationship to Aging in Cellular Aging and Cell Death, pp. 167-180, 1996. Wiley-Liss Inc., Editors: N.J. Holbrook, G. Martin, R. Lockshin. C. Miligan, L. Schwartz, Programmed O Cell Death During Development of Animals in Cellular Aging and Cell Death, pp. 181-208, 1996. Wiley-Liss Inc. P53-Dependent Apoptosis in Tumor Progression and in Cancer Therapy, Scott W. Lowe, H. Earl Ruley in Cellular Aging and Cell Death, pp. 209-234, 1996. Wiley-Liss, Inc.
- Appropriate dosages to increase the induction of apoptosis of non-neoplastic ovarian epithelial cells may be determined by those of skill in the art depending upon the identity of the Vitamin D compound and its method of administration.
- preferred dosages of the Vitamin D compound effective to increase apoptosis of non-neoplastic ovarial epithelial cells range from 0.0001 to 1.0 mg/kg of body weight (based upon the apoptotic potency of 1,25-dihydroxy vitamin D 3 ) with dosages ranging from about 0.005 to 0.75 mg/kg being more preferred and dosages of about 0.05 to 0.5 mg/kg being particularly preferred.
- a larger dosage of a Vitamin D compound might induce apoptosis in a large cohort of normal or dysplastic epithelial cells which over a period of time have become available for apoptosis. The treatment is then repeated some time later when another cohort of epithelial cells is capable of being induced for apoptosis. It is contemplated that one mode of administration may be administering the Vitamin D compound for a brief period sufficient to produce apoptotic
- Vitamin D compounds and progestins will exhibit not only additive but synergistic effects in the induction of apoptosis of non-neoplastic ovarian epithelial cells. In this manner the adverse physiological effects of administering larger quantities of Vitamin D compounds and of progestin products can be minimized.
- a progestin product may be administered at a dose higher than 10 mg daily of a norethindrone equivalent dose.
- the oral preparations currently on the market are: norgestrel
- Estrogen is the primary agent in hormone replacement therapy.
- Postmenopausal women are generally given estrogen alone, or with low doses of progestins.
- the hormones may be administered continuously or cyclically.
- Continuous administration is typically 0.625 mg Premarin ® (a conjugated equine estrogen) daily or its equivalent, with a 2.5 mg Provera ® (medroxyprogesterone acetate) daily.
- Cyclical administration is typically 25 consecutive days of 0.625 mg Premarin ® daily ,with 10 mg Provera ® daily on days 16 through 25, followed by 5 days of no hormone treatment (during which time these women will menstruate).
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002293582A CA2293582A1 (en) | 1997-06-11 | 1998-06-05 | Prevention of ovarian cancer by administration of a vitamin d compound |
EP98926371A EP0983070B1 (en) | 1997-06-11 | 1998-06-05 | Prevention of ovarian cancer by administration of a vitamin d compound |
DK98926371T DK0983070T3 (en) | 1997-06-11 | 1998-06-05 | Prevention of ovarian cancer by administration of a vitamin D compound |
DE69836134T DE69836134T2 (en) | 1997-06-11 | 1998-06-05 | PREVENTION OF EGG CANCER BY VITAMIN D COMPOUNDS |
AU78222/98A AU7822298A (en) | 1997-06-11 | 1998-06-05 | Prevention of ovarian cancer by administration of a vitamin compound |
CY20071100022T CY1105909T1 (en) | 1997-06-11 | 2007-01-08 | PREVENTION OF OVARIAN CANCER BY ADMINISTERING A VITAMIN D COMPOUND |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/873,010 | 1997-06-11 | ||
US08/873,010 US6034074A (en) | 1996-09-13 | 1997-06-11 | Prevention of ovarian cancer by administration of a Vitamin D compound |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998056389A1 true WO1998056389A1 (en) | 1998-12-17 |
Family
ID=25360805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/011737 WO1998056389A1 (en) | 1997-06-11 | 1998-06-05 | Prevention of ovarian cancer by administration of a vitamin d compound |
Country Status (11)
Country | Link |
---|---|
US (3) | US6034074A (en) |
EP (2) | EP1782814A1 (en) |
AT (1) | ATE342058T1 (en) |
AU (1) | AU7822298A (en) |
CA (1) | CA2293582A1 (en) |
CY (1) | CY1105909T1 (en) |
DE (1) | DE69836134T2 (en) |
DK (1) | DK0983070T3 (en) |
ES (1) | ES2275307T3 (en) |
PT (1) | PT983070E (en) |
WO (1) | WO1998056389A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6503893B2 (en) | 1996-12-30 | 2003-01-07 | Bone Care International, Inc. | Method of treating hyperproliferative diseases using active vitamin D analogues |
US6538037B2 (en) | 1991-01-08 | 2003-03-25 | Bone Care International, Inc. | Methods for preparation and use of 1α,24(S)-dihydroxyvitamin D2 |
US6566353B2 (en) | 1996-12-30 | 2003-05-20 | Bone Care International, Inc. | Method of treating malignancy associated hypercalcemia using active vitamin D analogues |
US6573256B2 (en) | 1996-12-30 | 2003-06-03 | Bone Care International, Inc. | Method of inhibiting angiogenesis using active vitamin D analogues |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6407082B1 (en) * | 1996-09-13 | 2002-06-18 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of a vitamin D compound |
US20040167106A1 (en) * | 1993-06-04 | 2004-08-26 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of a Vitamin D compound |
US6028064A (en) | 1996-09-13 | 2000-02-22 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of progestin products |
US6765002B2 (en) | 2000-03-21 | 2004-07-20 | Gustavo Rodriguez | Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium |
US6511970B1 (en) | 1996-09-13 | 2003-01-28 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium |
US6034074A (en) | 1996-09-13 | 2000-03-07 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of a Vitamin D compound |
US6087350A (en) * | 1997-08-29 | 2000-07-11 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of pretreatment chemicals to enhance efficacy of cytotoxic agents |
JP2002509888A (en) * | 1998-03-27 | 2002-04-02 | オレゴン ヘルス サイエンシーズ ユニバーシティー | Vitamin D and its analogs in the treatment of tumors and other hyperproliferative diseases |
US20050113351A1 (en) * | 2000-03-21 | 2005-05-26 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
US20040176336A1 (en) * | 2000-03-21 | 2004-09-09 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
US20010044431A1 (en) * | 2000-03-21 | 2001-11-22 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
US20050004007A1 (en) * | 2000-09-12 | 2005-01-06 | Steven Grant | Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitiors and cellular differentiation agents |
US7361664B2 (en) * | 2001-06-20 | 2008-04-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vitamin D receptor antagonists and related compositions and methods of use |
KR20050044655A (en) * | 2001-12-03 | 2005-05-12 | 노바세아, 인크. | Pharmaceutical compositions comprising active vitamin d compounds |
US20050026877A1 (en) * | 2002-12-03 | 2005-02-03 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
US20050020546A1 (en) * | 2003-06-11 | 2005-01-27 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
EP2435825B8 (en) | 2009-05-27 | 2015-09-02 | Biotempus Limited | Methods of treating diseases |
EP2513824A1 (en) * | 2009-12-17 | 2012-10-24 | Mayo Foundation for Medical Education and Research | Determination of favorable time(s) for chemotherapy delivery |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3608075A (en) | 1969-07-28 | 1971-09-21 | American Home Prod | Compositions and methods of treating the menopausal syndrome |
US3969502A (en) | 1972-04-14 | 1976-07-13 | Schering Aktiengesellschaft | Method for contraception by the administration of sequential contraceptive preparations |
DE2365103C3 (en) | 1973-12-21 | 1980-08-28 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Use of hormones for contraception |
US4390531A (en) | 1981-08-10 | 1983-06-28 | Syntex Pharmaceuticals International Ltd. | Method of contraception using peak progestogen dosage |
US4921843A (en) | 1988-10-20 | 1990-05-01 | Pasquale Samuel A | Contraception system and method |
US4628051A (en) | 1983-09-26 | 1986-12-09 | Ortho Pharmaceutical Corporation | Triphasic oral contraceptive |
US4544554A (en) | 1983-09-26 | 1985-10-01 | Ortho Pharmaceutical Corporation | Triphasic oral contraceptive |
US4616006A (en) | 1983-09-26 | 1986-10-07 | Ortho Pharmaceutical Corporation | Triphasic oral contraceptive |
US4530839A (en) | 1983-09-26 | 1985-07-23 | Ortho Pharmaceutical Corporation | Triphasic oral contraceptive |
US4931283A (en) | 1983-12-22 | 1990-06-05 | American Home Products Corp. (Del) | Menthol enhancement of transdermal drug delivery |
DE3347125A1 (en) | 1983-12-22 | 1985-07-11 | Schering AG, 1000 Berlin und 4709 Bergkamen | MULTI-STAGE COMBINATION PREPARATION AND ITS USE FOR ORAL CONTRACTION |
US4933184A (en) | 1983-12-22 | 1990-06-12 | American Home Products Corp. (Del) | Menthol enhancement of transdermal drug delivery |
US4760053A (en) | 1984-08-02 | 1988-07-26 | Fernand Labrie | Combination therapy for selected sex steroid dependent cancers |
US4962098A (en) | 1987-06-15 | 1990-10-09 | Warner-Lambert Company | Graduated estrogen contraceptive |
US4594340A (en) * | 1984-11-29 | 1986-06-10 | Hoffmann-La Roche Inc. | 25,26-dehydro-1α,24R-dihydroxycholecalciferol and 25,26-dehydro-1α,24S-dihydroxycholecalciferol and the epimeric mixture |
GB8503940D0 (en) | 1985-02-15 | 1985-03-20 | Erba Farmitalia | 4-substituted androstendione derivatives |
US4800198A (en) * | 1985-04-23 | 1989-01-24 | Wisconsin Alumni Research Foundation | Method of inducing the differentiation of malignant cells with secosterol |
GB8517360D0 (en) | 1985-07-09 | 1985-08-14 | Erba Farmitalia | Substituted androsta-1,4-diene-3,17-diones |
US4817819A (en) | 1985-12-19 | 1989-04-04 | Berlex Laboratories, Inc. | Container for tablets |
GB8531747D0 (en) | 1985-12-24 | 1986-02-05 | Erba Farmitalia | 10beta-alkynylestrene derivatives |
GB8615092D0 (en) | 1986-06-20 | 1986-07-23 | Erba Farmitalia | Androst-4-ene-317-diones |
DK174724B1 (en) | 1986-07-15 | 2003-10-06 | Wyeth Corp | Use of a composition comprising an estrogen and a progestogen for the preparation of a dosage form to provide hormone replacement therapy and contraception for women during the premenopause and pack to provide the composition |
DE3625315A1 (en) | 1986-07-25 | 1988-01-28 | Schering Ag | 11SS- (4-ISOPROPENYLPHENYL) -ESTRA-4,9-DIENES, THEIR PRODUCTION AND THE PHARMACEUTICAL PREPARATIONS CONTAINING THEM |
US4833125A (en) * | 1986-12-05 | 1989-05-23 | The General Hospital Corporation | Method of increasing bone mass |
DE3702383A1 (en) | 1987-01-23 | 1988-08-04 | Schering Ag | 11SS-ALKINYLESTRENE AND -ESTRADIENE, THEIR PRODUCTION AND THEIR PHARMACEUTICAL PREPARATIONS CONTAINING THEM |
US5276022A (en) | 1987-09-24 | 1994-01-04 | Jencap Research Ltd. | Hormone preparation and method |
US5422119A (en) | 1987-09-24 | 1995-06-06 | Jencap Research Ltd. | Transdermal hormone replacement therapy |
US5256421A (en) | 1987-09-24 | 1993-10-26 | Jencap Research Ltd. | Hormone preparation and method |
US5108995A (en) | 1987-09-24 | 1992-04-28 | Jencap Research Ltd. | Hormone preparation and method |
JP2785023B2 (en) | 1987-12-30 | 1998-08-13 | ルセル―ユクラフ | Novel derivative of 17β-OH-19-norsteroid substituted at 17α position, process for its preparation, its use as drug and pharmaceutical composition containing it |
US4780497A (en) | 1988-02-12 | 1988-10-25 | The B. F. Goodrich Company | Reduced melt viscosity CPVC blends containing sulfur and various metal carbonate stabilizers |
WO1989010351A1 (en) * | 1988-04-21 | 1989-11-02 | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemis | Novel vitamin d analogues |
US5246925A (en) * | 1989-03-09 | 1993-09-21 | Wisconsin Alumni Research Foundation | 19-nor-vitamin D compounds for use in treating hyperparathyroidism |
US5364847A (en) | 1989-03-10 | 1994-11-15 | Endorecherche | Inhibitors of sex steroid biosynthesis and methods for their production and use |
US5401731A (en) * | 1989-06-29 | 1995-03-28 | Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Productionsaktieselskab) | Vitamin D analogues |
GB8915770D0 (en) * | 1989-07-10 | 1989-08-31 | Leo Pharm Prod Ltd | Chemical compounds |
US4954790A (en) | 1989-11-15 | 1990-09-04 | Avantek, Inc. | Enhanced coupled, even mode terminated baluns, and mixers and modulators constructed therefrom |
FR2656309B1 (en) | 1989-12-22 | 1992-05-07 | Roussel Uclaf | NEW STEROUID PRODUCTS COMPRISING IN POSITION 10, A SUBSTITUTED ETHYL RADICAL, THEIR PREPARATION METHOD, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
FR2656310B1 (en) | 1989-12-22 | 1992-05-07 | Roussel Uclaf | NEW STEROUID PRODUCTS COMPRISING IN POSITION 10, A SUBSTITUTED THIOETHYL RADICAL, THEIR PREPARATION METHOD AND THE INTERMEDIATES THEREOF, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
GB8929059D0 (en) * | 1989-12-22 | 1990-02-28 | Leo Pharm Prod Ltd | Chemical compounds |
US5532228A (en) * | 1990-02-06 | 1996-07-02 | Schering Aktiengesellschaft | Side-chain homologous vitamin D derivatives, process for their production, pharmaceutical preparations containing these derivatives and their use as pharmaceutical agents |
US5227375A (en) | 1990-02-08 | 1993-07-13 | Endorecherche, Inc. | Aromatase inhibitors |
GB9007236D0 (en) * | 1990-03-30 | 1990-05-30 | Leo Pharm Prod Ltd | Chemical compounds |
US5314694A (en) | 1990-10-29 | 1994-05-24 | Alza Corporation | Transdermal formulations, methods and devices |
IE71203B1 (en) | 1990-12-13 | 1997-02-12 | Akzo Nv | Low estrogen oral contraceptives |
IE71202B1 (en) | 1990-12-17 | 1997-02-12 | Akzo Nv | Progestagen-only contraceptive |
IE62665B1 (en) | 1990-12-17 | 1995-02-22 | Akzo Nv | Contraceptive regimen |
DE4101953A1 (en) * | 1991-01-19 | 1992-07-23 | Schering Ag | 23-OXA DERIVATIVES IN THE VITAMIN-D SERIES, METHOD FOR THE PRODUCTION THEREOF THE PHARMACEUTICAL PREPARATIONS CONTAINING THESE DERIVATIVES AND THE USE THEREOF AS MEDICINAL PRODUCTS |
CH681153A5 (en) | 1991-01-28 | 1993-01-29 | Marigen S.A. | New and sterolester- sterolphosphorverbindungen. |
DE4104385C1 (en) | 1991-02-09 | 1992-08-13 | Marika Dr.Med. 6509 Framersheim De Ehrlich | |
US5278155A (en) * | 1991-06-05 | 1994-01-11 | Daikin Industries, Ltd. | Fluorine-containing vitamin D3 analogues and cell differentiation-inducing agent containing the same |
HU222501B1 (en) | 1991-06-28 | 2003-07-28 | Endorecherche Inc. | Controlled release pharmaceutical composition containing mpa or mga and process for its preparation |
ZA924811B (en) | 1991-06-28 | 1993-12-29 | Endorecherche Inc | Controlled release systems and low dose androgens |
DE4141746A1 (en) * | 1991-12-13 | 1993-06-17 | Schering Ag | 20-METHYL-SUBSTITUTED VITAMIN D DERIVATIVES |
US5210081A (en) | 1992-02-26 | 1993-05-11 | American Home Products Corporation | Alkali metal 8,9-dehydroestrone sulfate esters |
US5274142A (en) * | 1992-03-12 | 1993-12-28 | The Johns Hopkins University | Vitamin D3 analogues |
CA2096105A1 (en) * | 1992-10-07 | 1994-04-08 | Enrico Giuseppe Baggiolini (Deceased) | Vitamin d3 fluorinated analogs |
GB9226877D0 (en) * | 1992-12-23 | 1993-02-17 | Leo Pharm Prod Ltd | Chemical compounds |
JPH07506120A (en) | 1993-02-18 | 1995-07-06 | フアルマシア・エ・アツプジヨン・エツセ・ピー・アー | Fluorinated 4-aminoandrostadienone derivative and method for producing the same |
US5468736A (en) | 1993-02-25 | 1995-11-21 | The Medical College Of Hampton Road | Hormone replacement therapy |
US5547947A (en) * | 1993-03-11 | 1996-08-20 | Hoffmann-La Roche Inc. | Methods of treatment |
DE4308406C1 (en) | 1993-03-12 | 1994-06-16 | Jenapharm Gmbh | Contraceptive compsn. with reduced hormone dose and reduced side-effects - contg. synergistic mixt. of biogenic, synthetic oestrogen and gestagen |
EP0619306B1 (en) * | 1993-04-05 | 1996-09-11 | Wisconsin Alumni Research Foundation | 19-Nor-vitamin D3 compounds with substituent at 2-position |
US5380720A (en) * | 1993-05-11 | 1995-01-10 | Wisconsin Alumni Research Foundation | Iodo vitamin D3 compounds and method for preparing same |
US5486511A (en) | 1993-05-25 | 1996-01-23 | Merrell Dow Pharmaceuticals Inc. | 4-amino-17β-(cyclopropyloxy)androst-4-en-3-one, 4-amino-17β-(cyclopropylamino)androst-4-en-3-one and related compounds as C17-20 lyase and 5α-reductase |
US5595970A (en) | 1993-07-16 | 1997-01-21 | Schering Aktiengesellschaft | Treatment of climacteric disorders with nitric oxide synthase substrates and/or donors |
US5565589A (en) * | 1993-11-03 | 1996-10-15 | Wisconsin Alumni Research Foundation | 17-formyl-5,6-trans-vitamin D compounds |
US5428029A (en) * | 1993-11-24 | 1995-06-27 | Hoffmann-La Roche Inc. | Vitamin D3 fluorinated analogs |
US5373004A (en) * | 1993-11-24 | 1994-12-13 | Wisconsin Alumni Research Foundation | 26,28-methylene-1α, 25-dihydroxyvitamin D2 compounds |
US5811416A (en) | 1994-06-06 | 1998-09-22 | Board Of Regents The University Of Texas System | Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate |
US5633011A (en) | 1994-08-04 | 1997-05-27 | Alza Corporation | Progesterone replacement therapy |
IL115659A (en) | 1994-10-27 | 2000-06-01 | Akzo Nobel Nv | Steroids with a 17-spiromethylene lactone or lactol group process for their preparation and pharmaceutical compositions containing them |
IL116433A (en) | 1994-12-19 | 2002-02-10 | Galen Chemicals Ltd | INTRAVAGINAL DRUG DELIVERY DEVICES FOR THE ADMINISTRATION OF 17β-OESTRADIOL PRECURSORS |
CN1188189C (en) | 1995-06-07 | 2005-02-09 | 奥瑟-麦内尔制药公司 | Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with estrogen |
US5897539A (en) | 1995-09-28 | 1999-04-27 | Schering Aktiengesellschaft | Hormone replacement therapy method and hormone dispenser |
EP0889972B1 (en) | 1996-01-17 | 2007-06-13 | Sequenom-Gemini Limited | Use of the determination of polymorphims in the promoter region of the TGF-beta 1 gene in diagnosis |
GB9604305D0 (en) | 1996-02-29 | 1996-05-01 | Ralston Stuart H | Diagnostic method and apparatus |
US5898038A (en) | 1996-03-19 | 1999-04-27 | Board Of Regents, The University Of Texas System | Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors |
US5827876A (en) | 1996-04-09 | 1998-10-27 | American Home Products Corporation | Inhibition of bone loss by 3-(4-acrylamidobenzoyl) benzo b!-thiophenes |
US5880137A (en) | 1996-04-19 | 1999-03-09 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
US5985910A (en) | 1996-04-19 | 1999-11-16 | American Home Products Corporation | 3- [4- (2- Phenyl-Indole-1-ylmethyl) Phenyl]- Acrylamides as estrogenic agents |
US5747480A (en) | 1996-05-08 | 1998-05-05 | American Home Products Corporation | Oral contraceptive |
US5783208A (en) | 1996-07-19 | 1998-07-21 | Theratech, Inc. | Transdermal drug delivery matrix for coadministering estradiol and another steroid |
US5888543A (en) | 1996-07-26 | 1999-03-30 | American Home Products Corporation | Oral contraceptives |
US5858405A (en) | 1996-07-26 | 1999-01-12 | American Home Products Corporation | Oral contraceptive |
US6028064A (en) | 1996-09-13 | 2000-02-22 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of progestin products |
US6034074A (en) | 1996-09-13 | 2000-03-07 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of a Vitamin D compound |
US5994337A (en) | 1997-01-13 | 1999-11-30 | Wake Forest University | Effects of 17α-dihydroequilenin on plasma lipid and lipoprotein, glucose, insulin concentrations, coronary artery vasomotor function, and reproductive organ and mammary gland proliferation in atherosclerotic mammals |
US5948775A (en) | 1997-03-19 | 1999-09-07 | American Home Products Corporation | 2- or 3-(substitutedaminoalkoxyphenyl)quinazolin-4-ones |
US5891868A (en) | 1997-11-21 | 1999-04-06 | Kaiser Foundation Health Plan, Inc. | Methods for treating postmenopausal women using ultra-low doses of estrogen |
US6001846A (en) | 1998-02-17 | 1999-12-14 | Ligand Pharmaceuticals Incorporated | Process for the preparation of 1,2-dihydroquinolines |
US6020328A (en) | 1998-03-06 | 2000-02-01 | Research Triangle Institute | 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
US5962444A (en) | 1998-05-29 | 1999-10-05 | Research Triangle Institute | 17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
-
1997
- 1997-06-11 US US08/873,010 patent/US6034074A/en not_active Expired - Fee Related
-
1998
- 1998-06-05 WO PCT/US1998/011737 patent/WO1998056389A1/en active IP Right Grant
- 1998-06-05 AU AU78222/98A patent/AU7822298A/en not_active Abandoned
- 1998-06-05 PT PT98926371T patent/PT983070E/en unknown
- 1998-06-05 DK DK98926371T patent/DK0983070T3/en active
- 1998-06-05 CA CA002293582A patent/CA2293582A1/en not_active Abandoned
- 1998-06-05 AT AT98926371T patent/ATE342058T1/en not_active IP Right Cessation
- 1998-06-05 EP EP06021120A patent/EP1782814A1/en not_active Withdrawn
- 1998-06-05 DE DE69836134T patent/DE69836134T2/en not_active Expired - Fee Related
- 1998-06-05 EP EP98926371A patent/EP0983070B1/en not_active Expired - Lifetime
- 1998-06-05 ES ES98926371T patent/ES2275307T3/en not_active Expired - Lifetime
-
2000
- 2000-01-07 US US09/479,021 patent/US6444658B1/en not_active Expired - Fee Related
-
2007
- 2007-01-08 CY CY20071100022T patent/CY1105909T1/en unknown
- 2007-10-31 US US11/931,951 patent/US20080171731A1/en not_active Abandoned
Non-Patent Citations (8)
Title |
---|
CHRISTOPHERSON, WAYNE A. ET AL: "Responsiveness of human carcinoma cells of gynecologic origin to 1,25-dihydroxycholecalciferol", AM. J. OBSTET. GYNECOL. (1986), 155(6), 1293-6 CODEN: AJOGAH;ISSN: 0002-9378, XP002079316 * |
MOORE T B ET AL: "Differentiating effects of 1,25-dihydroxycholecalciferol (D3) on LA-N-5 human neuroblastoma cells and its synergy with retinoic acid.", JOURNAL OF PEDIATRIC HEMATOLOGY/ONCOLOGY, (1995 NOV) 17 (4) 311-7. JOURNAL CODE: B57. ISSN: 1077-4114., United States, XP002079318 * |
RUSTIN, G. J. S. ET AL: "Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer", BR. J. CANCER (1996), 74(9), 1479-1481 CODEN: BJCAAI;ISSN: 0007-0920, XP002079313 * |
SAUNDERS D E ET AL: "NONREPRODUCTIVE HORMONES AS BIOLOGIC MODIFIERS IN OVARIAN CARCINOMAS.", TWENTY-FOURTH ANNUAL MEETING OF THE SOCIETY OF GYNECOLOGIC ONCOLOGISTS, FEBRUARY 7-10, 1993. GYNECOL ONCOL 49 (1). 1993. 118. CODEN: GYNOA3 ISSN: 0090-8258, XP002079317 * |
SAUNDERS D E ET AL: "REPRESSION OF C-MYC EXPRESSION IN OVARIAN CARCINOMA CELLS BY 1 25 DIHYDROXYVITAMIN D-3.", TWENTY-THIRD ANNUAL MEETING OF THE SOCIETY OF GYNECOLOGIC ONCOLOGISTS, MARCH 15-18, 1992. GYNECOL ONCOL 45 (1). 1992. 83-84. CODEN: GYNOA3 ISSN: 0090-8258, XP002079315 * |
SAUNDERS, D. E. ET AL: "Inhibition of breast and ovarian carcinoma cell growth by 1,25-dihydroxyvitamin D3 combined with retinoic acid or dexamethasone", ANTI-CANCER DRUGS (1995), 6(4), 562-9 CODEN: ANTDEV;ISSN: 0959-4973, XP002079311 * |
SAUNDERS, D. E. ET AL: "Inhibition of c-myc in breast and ovarian carcinoma cells by 1,25-dihydroxyvitamin D3, retinoic acid and dexamethasone", ANTI-CANCER DRUGS (1993), 4(2), 201-8 CODEN: ANTDEV;ISSN: 0959-4973, XP002079312 * |
SAUNDERS, DWIGHT E. ET AL: "Receptors for 1,25-dihydroxyvitamin D3 in gynecologic neoplasms", GYNECOL. ONCOL. (1992), 44(2), 131-6 CODEN: GYNOA3;ISSN: 0090-8258, XP002079314 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6538037B2 (en) | 1991-01-08 | 2003-03-25 | Bone Care International, Inc. | Methods for preparation and use of 1α,24(S)-dihydroxyvitamin D2 |
US6503893B2 (en) | 1996-12-30 | 2003-01-07 | Bone Care International, Inc. | Method of treating hyperproliferative diseases using active vitamin D analogues |
US6566353B2 (en) | 1996-12-30 | 2003-05-20 | Bone Care International, Inc. | Method of treating malignancy associated hypercalcemia using active vitamin D analogues |
US6573256B2 (en) | 1996-12-30 | 2003-06-03 | Bone Care International, Inc. | Method of inhibiting angiogenesis using active vitamin D analogues |
US6680309B2 (en) | 1996-12-30 | 2004-01-20 | Bone Care International, Inc. | Method of treating hyperproliferative diseases using active vitamin D analogues |
Also Published As
Publication number | Publication date |
---|---|
EP0983070B1 (en) | 2006-10-11 |
AU7822298A (en) | 1998-12-30 |
ES2275307T3 (en) | 2007-06-01 |
US6034074A (en) | 2000-03-07 |
PT983070E (en) | 2007-02-28 |
CY1105909T1 (en) | 2011-02-02 |
DK0983070T3 (en) | 2007-02-05 |
DE69836134D1 (en) | 2006-11-23 |
CA2293582A1 (en) | 1998-12-17 |
EP1782814A1 (en) | 2007-05-09 |
US6444658B1 (en) | 2002-09-03 |
US20080171731A1 (en) | 2008-07-17 |
DE69836134T2 (en) | 2007-08-23 |
ATE342058T1 (en) | 2006-11-15 |
EP0983070A1 (en) | 2000-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080171731A1 (en) | Prevention of ovarian cancer by administration of a vitamin d compound | |
AU762481B2 (en) | Vitamin d and its analogs in the treatment of tumors and other hyperproliferative disorders | |
Gulliford et al. | A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer | |
AU723835B2 (en) | Method of treating prostatic diseases using active vitamin D analogues | |
US20080234238A1 (en) | Pharmaceutical product containing progestin, genistein, and vitamin d compound | |
JP2002516307A (en) | 1α-hydroxy-25-ene-vitamin D, analogs and uses thereof | |
US20070010500A1 (en) | Prevention of ovarian cancer by administration of a vitamin D compound | |
Fentiman et al. | Tamoxifen and benign breast problems | |
US6511970B1 (en) | Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium | |
US6765002B2 (en) | Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium | |
Takamoto et al. | Effect of 1α-hydroxycholecalciferol on psoriasis vulgaris: A pilot study | |
US20040167106A1 (en) | Prevention of ovarian cancer by administration of a Vitamin D compound | |
US20050187201A1 (en) | Use of 2-methylene-19-nor-20(S)-1alpha,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases | |
Araujo et al. | Vitamin D therapy in psoriasis | |
US20050113351A1 (en) | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium | |
CZ235599A3 (en) | Inhibition of hyperproliferative activity of neoplastic or hyperplastic cells of human prostate and pharmaceutical preparation for this purpose | |
JPH05194239A (en) | Therapeutic agent for hot flash caused by oval deletion | |
MXPA00011215A (en) | 1&agr;-HYDROXY-25-ENE-VITAMIN D, ANALOGS AND USES THEREOF |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CN JP MX |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2293582 Country of ref document: CA Ref country code: CA Ref document number: 2293582 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998926371 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1999502989 Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1998926371 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998926371 Country of ref document: EP |